Compare SMX & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMX | TNDM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | SMX | TNDM |
|---|---|---|
| Price | $19.65 | $20.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $24.06 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 04-23-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,007,001,000.00 |
| Revenue This Year | N/A | $8.59 |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 17.87 |
| 52 Week Low | $3.12 | $9.98 |
| 52 Week High | $16,266.53 | $37.93 |
| Indicator | SMX | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 46.66 |
| Support Level | $20.75 | $19.61 |
| Resistance Level | $26.26 | $21.98 |
| Average True Range (ATR) | 7.76 | 1.17 |
| MACD | -2.67 | -0.33 |
| Stochastic Oscillator | 14.49 | 29.49 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.